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Abstract
Background: Small molecule inhibitor of tyrosine kinase activity, compound SU11274, was reported to have
antitumorigenic and antimetastatic effect in melanoma. In this study, we evaluated, whether similar effect could
be achieved also in other melanoma cells including highly tumorigenic and hypermetastatic variant.
Methods: The effect of SU11274 was evaluated in adherent and non-adherent melanosphere cultures of human
melanoma cells M14, M4Beu, A375 and EGFP-A375/Rel3. Tumorigenicity of SU11274-treated cells was tested by
limiting dilution assay in xenograft model in vivo.
Results: Here we show that SU11274 enriched for melanoma-initiating cells in vivo. SU11274 substantially decreased
number of cells in adherent and spheroid cultures, but increased their tumorigenic potential as determined by higher
frequency of tumor-initiating cells in vivo. SU11274 treatment was not associated with any significant alteration in the
expression of stem cell markers, but the inhibitor stimulated higher level of pluripotent markers. SU11274-treated
melanoma cells exhibited higher ATP content and lactate release indicative of increased glycolysis. Our data
suggest that the SU11274 altered bioenergetic state of the cells. Indeed, pharmacological intervention with a
glycolytic inhibitor dichloroacetate significantly reduced SU11274-promoted increase in melanoma-initiating cells
and decreased their tumorigenicity.
Conclusions: Our data suggest critical role of glycolysis regulation in melanoma-initiating cells. Moreover, these
data unravel substantial plasticity of melanoma cells and their adoptive mechanisms, which result in ambivalent
response to therapeutic targeting.
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Background
Small molecule inhibitor SU11274 was initially developed
to specifically inhibit c-Met receptor signaling [1]. Recep-
tor tyrosine kinase c-Met is a receptor for hepatocyte
growth factor/scatter factor (HGF), pleiotropic cytokine
controlling pro-migratory, anti-apoptotic and mitogenic
signals [2]. c-Met activation evokes biological responses,
globally referred to as ‘invasive growth’, thus being poten-
tial therapeutic target in metastatic cancer [3]. Promise of
anti-c-Met drugs is based on their activity on multiple
stages of cancer development, from initiation through
progression to metastasis [4]. Moreover, the inappropriate
c-Met signaling occurs in virtually all types of solid tu-
mors [5]. In our previous study we have confirmed high
expression of the c-Met receptor in a model cell line
EGFP-A375/Rel3 derived as hypermetastatic and highly
tumorigenic variant of human melanoma cell line A375
[6]. Our experiments in the above mentioned study
have shown antiproliferative effect of SU11274 in vitro,
but tumor supporting effect in vivo (see Fig. 6), when used
as an augmentation to support antitumor effect of gene
therapy-based approach [6]. It has been reported that the
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intraperitoneal administration of SU11274 achieved sig-
nificant inhibitory effect on liver metastasis induced by
the intrasplenic injection of human metastatic melanoma
cells the HT168-M1 [7]. Moreover, the intratumor injec-
tion of SU11274 had high efficacy in vivo and this treat-
ment reduced tumor volume by 7-fold as compared with
control tumors induced by RU-P melanoma cells [8]. Based
on the findings we wanted to explore the effect of SU11274
on various melanoma cell lines including our model of
hypermetastatic variant, which was not examined so far.
Bulk tumor comprises subpopulations of non-tumorigenic
and tumorigenic cells, which can reversibly transit among
their states (tumorigenic stem cells vs. non-tumorigenic
cells) [9]. Tumor-initiating cells (tumorigenic or so-called
cancer stem cells) give rise to tumors in transplantation
assays in vivo and they were associated with specific sur-
face markers in human melanoma [10, 11]. Experiments
suggested significant level of plasticity in melanoma cells
and many markers were reversibly turned on and off in a
manner that did not correlate with the ability to form a
tumor [12–14]. Growth of tumor cells in three-dimensional
multicellular tumor spheroid cultures enables to maintain
their tumorigenic potential [15–17]; and therefore we sug-
gested to use it to explore the effect of SU11274 treatment
on tumor initiating potential of melanoma cells. It was pre-
viously shown that decreased tumor sphere formation by
the inhibition of c-Met correlated with preventing meta-
static disease and inhibiting stem cell function in pancreatic
carcinoma [18].
There is not much known about the metabolic regula-
tion of cancer stem cell function, but bioenergetic modu-
lation was shown to counteract stem cell features and
sensitized cells to kinase inhibitors [19–22]. Bioenergetic
modulators could be actually used in the antitumor treat-
ment [21, 23, 24]; but recent evidence suggested specific
metabolic behavior of melanoma cells [25, 26]. These re-
ports prompted us to test potential of bioenergetic modu-
lation to interfere with the tumor initiation in melanoma.
We evaluated the effect of SU11274 inhibitor in both
adherent and spheroid melanoma cultures in vitro; and
the effect on tumor growth and initiation in vivo. Our
data show that SU11274-treated cells were enriched for
melanoma-initiating cells; they had significantly increased
tumorigenic potential. This effect could be counteracted




Following reagents were purchased from Sigma-Aldrich
(St. Louis, MO): SU11274, dacarbazine (DACA), dichloroa-
cetate (DCA), 3-bromo-pyruvate (3BrPA). Crizotinib (Pfizer
Inc., Mission, KS) was kindly provided by the National
Cancer Institute, Bratislava.
Cells and cell lines
Human malignant melanoma cell lines A375 (ATCC®
CRL-1619™), M14 and M4Beu [27] (kindly provided by
Dr. Bizik, CRI BMC SAS Bratislava) were propagated in
DMEM medium supplemented with 5 % of fetal bovine
serum, glutamine, penicillin/streptomycin and ampho-
tericin. Cell lines EGFP-A375 and EGFP-A375/Rel3 were
derived as described [6, 28]. EGFP-A375/Rel3 cells will
be designated Rel3 (3rd relapse) for the rest of the study.
These cells were derived by expansion of tertiary relapse
of tumors after in vivo treatment with prodrug converting
cell-based gene/prodrug therapy approach.
Melanosphere culture was performed in ultra-low ad-
herent plates and serum-free medium supplemented
with B27, EGF and bFGF as described in detail elsewhere
[29]. Usually 5–10,000 melanoma cells per 3 ml culture
media per well was cultured in 6-well plates for 7 days.
Melanospheres were collected by centrifugation, dissoci-
ated by trypsinization, viable cell count was determined
by trypan blue exclusion assay and single cell suspension
was used for further cultivation or treatments. In order
to assess cellular morphology, cell or spheroid images
were taken by the IncuCyte ZOOM™ Kinetic Imaging
System (Essen BioScience, Welvyn Graden City, UK).
Cell confluence was calculated by the IncuCyte ZOOM
software 2012A.
ATP and cell viability assay
Relative ATP content per cell was determined by the
CellTiter-Glo™ Luminescent Cell Viability Assay (Promega
Corporation, Madison, WI). Cells were counted using try-
pan blue exclusion assay, 50–100 μl cell suspension was
mixed with equal volume of the luminescent reagent and
luminescence in relative luminescent units (RLU) was
determined on the LumiStar GALAXY reader (BMG
Labtechnologies, Offenburg, Germany).
Relative viability of the cells was measured by the same
method. In the adherent conditions, cells were plated at
1500–2000 cells/100 μl media per well in 96-well white-
walled plates, let to adhere for 24 h, supplemented with
the drug(s) to reach indicated final concentration and
treated for 3–5 days. In the melanosphere conditions, 500
cells/100 μl media per well in 96-well ultra-low attach-
ment plates were supplemented with the indicated com-
pounds and treated for 5–7 days. At the end of the
melanosphere experiment, luminescent reagent was added
to the wells (ratio 1:1), incubated for 15 min at room
temperature, lysate transferred to the white walled 96-well
plates and a relative luminescence was measured as above.
Experiments were performed in quadruplicates at least
four times with similar results and the representative re-
sult is shown, the average relative luminescence of the
cells without any treatment was set to 100 % and calcu-
lated relative values were expressed as means + SD.
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Chemiluminescent BrdU cell proliferation ELISA
Triplicates of 3000 Rel3 cells per well were seeded in 96-
well black-walled plates 24 h prior to the treatment start.
Cells were treated with the indicated concentration of
SU11274 for 6 days. BrdU was added to the wells 18 h
prior to evaluation. Time and the drug doses were chosen
based on preliminary experiments (not shown). BrdU
incorporation was determined by the Cell Proliferation
ELISA, BrdU (chemiluminescent, Roche Diagnostics,
Mannheim, Germany) on the LUMIstar GALAXY reader
(BMG Labtechnologies, Offenburg, Germany). BrdU in-
corporation of the cells incubated without any treatment
was taken as 100 % by default. Values were expressed as
an average of relative BrdU incorporation + SD. Experi-
ments were repeated twice with similar results and a rep-
resentative outcome is shown.
Glucose uptake and lactate release assay
Measurement of the glucose uptake was done with the
Glucose Uptake Colorimetric Assay Kit (BioVision Inc.,
Milpitas, CA). Melanoma cells were treated for 7 days
with 1 μM SU11274 inhibitor, counted and resuspended
to obtain 500,000 cells per 0.5 ml media. 2-deoxyglucose
was added to the suspension and a measurement pro-
ceeded according to the manufacturer’s protocol. Lactate
release from the treated cells was determined by Lactate
Colorimetric Assay Kit II (BioVision Inc., Milpitas, CA).
Treated cells were seeded at a density of 500,000 cells/
well/0,5 ml media in 24-well plates for 16 h. Medium
was discarded after incubation, cells were lysed in the re-
action mix and the analysis proceeded as recommended
in the manufacturer’s protocol. Values were determined
on xMark™ Microplate Absorbance Spectrophotometer
(Bio-Rad Laboratories, Hercules, CA). Experiment was
repeated at least twice, each value determined in tripli-
cates and a representative outcome is shown.
Flow cytometry
For the detection of the expression of surface markers,
anti-human c-Met-PE (Sino Biological Inc. Beijing, China)
antibodies were used. Dead cells were excluded based on
the DAPI (4′, 6-diamidino-2-phenylindole) staining. Cells
were analyzed using BD Canto II cytometer (Beckton
Dickinson, Franklin Lakes, NJ) equipped with FACSDiva
program. FCS Express software was used for the evaluation.
Protein arrays and analysis
Proteome profile of the melanosphere cells cultured for
7 days in the presence of 1 μM SU11274 was evaluated
by the Proteome Profiler™ Human Phospho-Kinase Anti-
body Array and the Human Pluripotent Stem Cell Anti-
body Array (R&D Systems™ Inc., Minneapolis MN). Cells
were dissociated, counted and lysed in a lysis buffer at a
concentration of 107 per ml. Protease inhibitors were
added to the lysis buffer for the pluripotent stem cell array
at recommended concentration (Complete Protease In-
hibitor Cocktail Tablets, Roche Diagnostics Deutschland
GmbH, Mannheim, Germany). Protein lysate (350 μg
total protein) was loaded on the membranes with blot-
ted antibodies and evaluated as recommended by the
manufacturer.
Phoshorylation status of c-Met was analyzed by western
blotting. Cells were lysed in buffer containing 50 mM Tris
HCl (pH 7.4), 1 % NP40, 0,5 % SDS, 150 mM NaCl, 2 mM
EDTA, 50 mM NaF, 0,2 mM sodium ortho-vanadate
(Na3VO4), and protease inhibitor cocktail tablets Complete
(Roche, cat. no. 04 693 116 001). Lysates were prepared for
SDS-PAGE by adding 10 μg of protein to 4× Laemelli’s
loading buffer (Bio-Rad, cat. no. 161-0747). Samples were
denatured at 95 °C for 4 min and centrifuged for 30 s at
5000 rpm, prior to electrophoresis. Protein samples were
loaded onto a 10 % polyacrylamide gel (Bio-Rad, TGX
Stain-Free FastCast Acrylamide Kit, 10 %, Cat. No. 161-
0183) and electrophoresed for 1 h at 200 V in a Mini-
Protean Tetra Cell (Bio-Rad, Cat. No.165-8004) using
10× Tris/Glycine/SDS Running buffer pH 8.3 (Bio-Rad,
cat. no. 161-0732). Proteins were transferred onto a
nitrocellulose membrane using the Mini Trans-Blot
Cell Module (Bio-Rad, cat. no. 1703811) in a transfer
buffer (10× Tris/Glycine/SDS Buffer pH 8.3 and 20 %
methanol) at 100 V for 1 h. Specific phospho-Met antibody
(Tyr1349, 130H2, rabbit mAb, Cell Signaling Technologies,
cat. no. 3133) was used, monoclonal Anti-β-actin (SIGMA-
ALDRICH, cat. no. A1978) served as a loading control.
Immunoblots were visualized using enhanced chemilu-
minescence (Bio-Rad, Clarity Western ECL Substrate,
cat. no. 170-5060).
In vivo animal studies
Project was performed in the approved animal facility
(licence number SK PC 14011) as approved by the institu-
tional ethic committee and by the national competence au-
thority (State Veterinary and Food Administration of the
Slovak Republic, registration number Ro 3108/14-221) in
compliance with the Directive 2010/63/EU of the European
Parliament and the European Council and the Regulation
377/2012 on the protection of animals used for scientific
purposes. Six weeks-old athymic nude mice (Balb/c-nu/nu)
were used in accordance with the institutional guidelines
under the approved protocols. It was determined in the
preliminary studies that the 106 of EGFP-A375 cells exhib-
ited 100 % tumor penetrance when injected s.c. in a serum-
free medium. In order to compare the tumorigenicity of
melanoma cells, gradually decreasing numbers of EGFP-
A375 and Rel3 cells were injected s.c. in the 100 μl serum-
free media. The frequency of the tumor-initiating cells was
determined by the extreme limiting dilution analysis
(ELDA) [30]. To evaluate the effect of SU11274 inhibitor
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on the tumor-initiating capabilities, melanoma cells were
treated with 1 μM SU11274 for 7 days in vitro and these
cells were injected 2 × 105/100 μl/mouse s.c. Tumor take
rates for the melanosphere cells was determined as a pro-
portion of tumors growing to all inoculations of given cell
number injected in the 1:1 serum free-DMEM diluted
matrigel (ECM Gel from Engelbreth-Holm-Swarm murine
sarcoma, Sigma-Aldrich). Both SU11274 treated and un-
treated cells in vitro were used to compare the tumor initi-
ating potential. In a synthetic lethality study, the cells from
the spheroid cultures in the presence of 1 μM SU11274
were treated for 24 h with the 5 mM DCA, 3.5 μM 3BrPA
or 100 μM dacarbazine (DACA) added on the day 4. Cells
were let to recover for 48 h in the presence of inhibitor
SU11274. Cells were collected by centrifugation, trypsi-
nized, counted and 20,000/site in 1:1 diluted ECM gel
injected s.c. to determine their potential for a tumor initi-
ation. The ATP level per well was determined as above in
the single cell suspension.
The animals were regularly inspected for the tumor in-
cidence and considered tumor-free when no palpable
rigid structure exceeding 1 mm3 could be detected.
Growing tumors were measured by the caliper and a
volume of tumor was calculated according to the for-
mula volume = length × width2/2. Results were evaluated
as median volume + (min, max). Animals were sacrificed,
when the tumors exceeded 1 cm3 in accordance with the
ethical guidelines or at the experiment endpoint. Animals
were designated tumor-free at the experiment endpoint,
when no tumor growth was detectable at necropsy.
Statistical analysis
The Student’s two-sample t-test was used for hypothesis
testing for the difference in means of two samples, as-
suming that both samples come from a normal distribu-
tion with the standard deviations unknown but assumed
equal. The Mann-Whitney U test was used to perform a
two-sided test of the hypothesis that two independent
samples come from distributions with equal medians.
The p-values with p < 0.05 were considered to be statisti-
cally significant.
Results
Recently we described novel hypermetastatic human
melanoma cell line EGFP-A375/Rel3 (designated Rel3 in
the following text) [6]. It was derived from parental
EGFP-A375 [28] by three rounds of consecutive in vivo
passaging as the third relapse which could regrow after
the experimental therapy with prodrug-converting mes-
enchymal stromal cells. Rel3 cell line is highly tumori-
genic and produces massive lung colonization upon
intravenous injection indicative of its aggressiveness. We
decided to examine the antitumor potential of SU11274 in
malignant melanoma cell lines M14, M4Beu [27], A375
[28] and Rel3 cells (derived hypermetastatic variant of
A375) [6]. We confirmed high level of the c-Met receptor
on cell surface by flow cytometry in these cells. The c-Met
expression was detected on the 46 % of M14 cells, 97.7 %
of M4Beu cells, 98.0 % of A375 cells and 95.2 % of Rel3
cells (Fig. 1a). SU11274 can inhibit HGF-stimulated phos-
phorylation of c-Met on Tyr1234/1235 [31]. C-Met is not
phosphorylated on these Tyr residues in A375 [32].
However, our data have shown that SU11274 increased
phosphorylation of c-Met on Tyr1349, which was phos-
phorylated in both A375 and Rel3 cells (Fig. 1b). In
addition to SU11274 as a selective c-Met inhibitor with
the IC50 of 10 nM in a cell-free assay, Crizotinib (PF-
02341066) as another ATP-competitive small-molecule
inhibitor of the catalytic activity of c-Met the IC50 of 11
nM and in cell-free assay was used [33, 34]. Examined
cell lines exhibited very similar IC50 for these two dif-
ferent c-Met inhibitors SU11274 ranging 4–5 μM
(Fig. 1c) and crizotinib ranging 1.25–3 μM (Fig. 1d) in
standard adherent cultures. SU11274 treatment caused
alteration in cellular morphology from narrow spindle
shape to flatter rounded morphology and less scattered
colonies (Fig. 2a). SU11274-treated cells were subse-
quently injected as xenografts and they were more
tumorigenic in vivo (Fig. 2b). When we injected 5 × 105
cells, the median tumor volume was significantly higher
in the SU11274-pretreated group - 721.2 mm3 versus
395.8 mm3 in control group by day 16). When 2 × 105
cells were injected, tumor take rate was also higher in
the SU11274-pretreated group with 4 out of 4 injected
tumors growing in contrast to the untreated group, where
only 2 out of 4 inoculates grew with a longer dormancy
period. Tumor growth kinetic is shown in (Fig. 2b).
In order to examine the effect of SU11274 on melanoma-
initiating cells we switched cells to non-adherent melano-
sphere cultures [35, 36]. M4Beu cells were not able to
proliferate under these conditions and did not form mela-
nospheres (Fig. 3a). M14, A375 and Rel3 cells propagated
and expanded in spheroid conditions (at least for more
than 10 consecutive passages). Direct comparison of adher-
ent and non-adherent cultures unraveled increased sensi-
tivity to SU11274 in melanospheres (Fig. 3b–d). SU11274
also significantly inhibited cell proliferation. There were
6.5 × 105 Rel3 cells in control versus 4.2 × 105 Rel3 cells
after SU11274 treatment, which is a 35 % inhibition of the
proliferation. (Fig. 2e). The effect of SU11274 on tumor ini-
tiation frequencies was evaluated by extreme limiting dilu-
tion assay (ELDA) [30]. We injected gradually decreasing
number of the cells after adherent and melanosphere cul-
ture and determined a proportion of growing tumors. For
adherent parental A375 cells, frequency of tumor initiating
cells was one in 8.5 × 105. Frequency of tumor initiating
cells in Rel3 was one in 2.4 × 105, which was 3.5 higher cor-
responding to increased tumorigenicity. More importantly,
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melanosphere cultures further increased the frequency of
tumor initiating cells to 1 out of 3.3 × 104 spheroid Rel3
cells (7-fold increase in comparison to adherent culture).
Tumor-initiating cell frequencies in SU11274-treated cells
was determined to be 1 out of 3289 cells (p value 1 × 10−5),
which was a 10-fold enrichment for tumor-initiating
cells by SU11274. Same effect was achieved in M14
cells, where stem cell frequencies determined in vivo
were 1 out of 3.8 × 104 spheroid M14 cells in contrast
to 1 out of 1.0 × 103 SU11274-treated spheroid M14 cells.
This represents a 4-fold enrichment in tumor initiating
cell frequency (Table 1).
Fig. 1 SU11274 and crizotinib inhibit melanoma cell proliferation. a Flow cytometry analysis of four different human melanoma cell lines confirmed high
expression of c-Met receptor. Anti-human c-Met-PE (Met, HGFR) antibody was used to detect positive cells, DAPI was used as a viability counterstain.
b Phosphorylation status of c-Met was examined by western blot. Tyr1349 is phosphorylated in A375 and Rel3, SU11274 further increased phosphorylation
in A375. c–d Adherent melanoma cells exhibited similar IC50 values for c-Met inhibitors SU11274 or crizotinib. Relative viability was determined
by luminescent viability assay on day 3. Values were calculated from the quadruplicates as means + SD
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Next, we evaluated a long-term serial propagation of
cells in the non-adherent conditions with or without
SU11274. Rel3 cells could be long-term propagated, al-
though the cumulative cell numbers differed significantly
due to the antiproliferative action of the inhibitor (Fig. 4a).
Cells from melanospheres were viable; they adhered and
proliferated after switching to adherent conditions. Cell
morphology after spheroid culture remained similar to
morphology of adherent cultures in the presence or ab-
sence of SU11274 shifted from irregular spiked shape to
flatter cobblestone morphology (Fig. 4b). Obvious discrep-
ancy between minor decrease in the viability and severe
decrease in the cell numbers mediated by SU11274 was
further examined by BrdU incorporation assay. DNA syn-
thesis and cell cycle progression was substantially more
inhibited in comparison to the decrease of ATP level mea-
sured by relative viability assay (Fig. 4c). Relative ATP-
content per 100,000 cells was significantly higher in cells
propagated in SU11274 (Fig. 4d). Further analysis con-
firmed no significant difference in the glucose uptake, but
higher lactate release from the SU11274-treated cells,
indicative of their higher dependence on (or a metabolic
switch to) aerobic glycolysis (Fig. 4e and f). No effect on
ATP levels/cells and tumorigenicity was be observed with
crizotinib (data not shown).
Next, we examined alterations induced by SU11274 on
pluripotent stem cell proteins and phosphokinase proteome
profile. Melanoma cells express many proteins associated
with pluripotency, but SU11274-treated spheroids have in-
creased levels in comparison to the untreated ones (Fig. 5a).
Higher level of these transcription factors correlates with
increased capability of the treated cells to induce tumor
growth. Phosphokinase proteome array demonstrated that
SU11274 activated p53 (Fig. 5b, lower panel b), which cor-
relates with inhibition of the cell proliferation shown in
Fig. 4a and c. RSK1/2/3 phosphorylation was increased
after SU11274 exposure. We detected phosphorylation of
following target kinases in Rel3 cells: ERK1/2, p-RAS40,
Akt 1/2/3, p38 alpha, AMPK alpha1, CREB, GSK-3 alpha/
beta, WNK-1 and HSP60 in both treated and untreated
cells.
Based on the previous data suggesting involvement of
bioenergetic modulation in SU11274-treated Rel3 cells,
we decided to test the ability of bioenergetic modulators
to suppress increased tumorigenicity of SU11274-treated
cells. Spheroid non-adherent cells were hypersensitive to
bioenergetic modulators dichloroacetate (DCA, inhibitor of
pyruvate dehydrogenase kinase [23]) and 3-bromopyruvate
(3BrPA, a hexokinase and GAPDH inhibitor [24]) in com-
parison to the adherent cells (Fig. 6a and b). Switch to mel-
anosphere cultures leads to higher cellular dependence on
the aerobic glycolysis, which correlates with increased
tumor initiating properties of melanosphere cells. Contrast-
ingly, chemotherapeutic alkylating agent dacarbazine, which
Fig. 2 Treatment with SU11274 alters morphology of melanoma cells and their tumorigenicity. a Treatment with 1 μM SU11274 induces inhibition of
cell proliferation and morphological alteration in Rel3 cells. Colonies of SU11274-treated cells appeared less scattered and formed tighter intercellular
junctions. Scale bar 200 μm. b Two × 105 of untreated or SU11274-treated Rel3 cells (1 μM SU11274 for 7 days in vitro) were injected subcutaneously
into the flank of immunodeficient mice. Tumor burden was significantly higher in xenografts from SU11274-treated cells, data show median tumor
volume with vertical bars depicting maximum and minimum tumor volume in group, *p ≤ 0.05
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was clinically approved for the treatment of malignant
melanoma [37], was significantly less toxic to spheroid
cells in comparison to adherent cells. This demon-
strated inherent drug resistance in cultures enriched for
melanoma-initiating cells (Fig. 6c). Finally, tumor take
rate of the cells treated with SU11274 combined with
selected compounds was examined by previously published
approach [38]. We expected that in vitro pretreatment
targeting tumor-initiating cells would eradicate these from
culture and lessen the tumorigenicity. Therefore, SU11274-
stimulated cells were co-treated with 3BrPA, DCA or
dacarbazine at the IC50 for 24 h. Dacarbazine was previ-
ously shown to spare the tumor initiating cells; thus, it was
used in this assay as a control. Cells were cultured for next
48 h to allow the cell death to occur and viable cells to
recover. Combination treatment with DCA did not signifi-
cantly change SU1174-mediated increase of the ATP con-
tent per cell. Compounds 3BrPA or dacarbazine further
increased relative ATP level (Fig. 6d). However, DCA de-
creased tumorigenicity of SU11274-treated cells in vivo,
which was not the case for SU11274 combination with
3BrPA or dacarbazine (Fig. 6f). Median tumor volume in
the SU11274-treated group was 115.5 mm3 in contrast to
14.5 mm3 in the DCA pulsed SU11274-treated cells. More-
over, three out of the eight animals did not develop any
tumor in contrast to the eight out of the eight in the
SU11274 group. DCA treatment alone did not significantly
change tumor take rates or median tumor volumes. Our
data show that antimelanoma chemotherapeutic drug
dacarbazine similarly to bioenergetics modulator 3BrPA
Fig. 3 Melanosphere propagation increases tumor cell sensitivity to SU11274. a Human melanoma cells were seeded into ultra-low attachment
plates in serum-free DMEM/F12 medium supplemented with B27, EGF and bFGF. M14, EGFP-A375 and Rel3 could be propagated and formed tight
melanospheres. Cell line M4Beu did not form spheroids and did not proliferate under these culture conditions. Scale bar 500 μm. b–d Sensitivity of the
adherent versus spheroid cultures to SU11274 was compared. Non-adherent melanoma cells M14, A375 and Rel3 were more sensitive to SU11274
inhibitor in comparison to adherent cells. Relative viability was determined by luminescent ATP-based viability assay after 5-day treatment. Values were
calculated from the quadruplicates as means + SD. e Spheroid cultures were initiated from the 5000 cells seeded per well in 6-well plates with or without
1 μM SU11274. Total number of cells per well was counted 7 days later. SU11274-treatment significantly reduced a number of cells in comparison to
untreated controls, *p < 0.05
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does not affect tumor initiating cell subpopulation in Rel3
cells. Combination of the DCA with SU11274 also did not
completely eradicate tumor initiation capabilities. We attri-
bute this outcome to the fact that melanoma cells derived
from A375 cells harbor mutated B-Raf (V600E), thus
tumor initiation capabilities without targeted inhibition of
hyperactivated oncogenic pathway were retained. SU11274
compound does not interfere with this signaling axis.
Discussion
In search for an agent to prevent both growth and meta-
static dissemination of melanoma cells we hypothesized
that the c-Met receptor was a suitable target [3]. How-
ever, experimental evidence suggested that c-Met recep-
tor plays a dual role in oncogenesis. (i) In the mutated,
amplified or otherwise genetically altered form, c-Met
generates and maintains transformed phenotype, and
drives clonal evolution; (ii) in the wild-type form, c-Met
contributes to maintain - in the cancer stem cell - the
phenotype ‘inherent’ in the stem/progenitor cell of origin
[4]. Extensive redundancy of the receptor-tyrosine kinase
signaling in cancer cells and receptor cross-talk suggested
that there might be inherent or acquired resistance medi-
ated by other signaling cascades compensating for inhibi-
tory effect of the particular small-molecule inhibitor [39].
We detected high surface expression of c-Met receptor in
tested melanoma cell lines (Fig. 1a). These cells did not
produce detectable HGF into cell culture medium thus
excluding c-Met autocrine stimulation (data not shown).
We focused predominantly on potential role of the c-Met
inhibitor SU11274 in highly metastatic aggressive variant
Rel3 [6], as it was suggested as efficient atimelanoma
agent [7, 8]. Antiproliferative activity of small molecule
inhibitor SU11274 in vitro, unexpectedly, was in contrast
to its protumorigenic effect on the Rel3 cells in vivo [6].
More importantly, SU11274 significantly increased fre-
quency of tumor initiating cells. We hypothesize that
there might be several reasons for the protumorigenic
outcome including individual response of given model
cell line, different route of administration or experi-
mental setup. Although intraperitoneal administration
of SU11274 decreased metastatic burden in liver of intras-
plenically injected mice in orthotopic model [7], the same
route of administration supported tumor growth of sub-
cutaneously xenografted melanoma cells Rel3 in hetero-
topic model (Fig. 2b). Etnyre et al. [8] achieved antitumor
effect by direct intratumor injection of compound in model
melanoma. Taken together these data stress extreme plasti-
city of melanoma cells and context-dependent nature be-
tween protumorigenic and antitumorigenic action of small
molecule inhibitor.
Hierarchical organization of melanoma remains a mat-
ter of a debate. It was shown that melanoma cells pos-
sess considerable plasticity and represent a tumor type
with shallow if any hierarchy [16]. Our data support this
notion as we detected high expression of pluripotent pro-
teins in unaffected Rel3 cells. Switching melanoma cells to
spheroid non-adherent culture conditions further enriched
for melanoma-initiating cells as confirmed by the in vivo
assay. We were able to propagate the melanospheres
long-term both with or without SU11274 (more than
10 passages corresponding to more than 10 weeks) thus
demonstrating the presence of self-renewing cells in vitro
and no detrimental effect of the SU11274 on them. We
have examined surface marker expression with a particular
focus on putative melanoma cancer stem cell markers [10].
We could not find any significant alteration (up- or down-
regulation) in any of these markers tested such as c-Kit,
CD271, CD133, ABCB5, ABCB1, ALDH1 in the SU11274-
treated cells versus the untreated ones (data not shown).
Non-adherent culture conditions did not alter melanoma
differentiation marker CD146 (M-CAM). It also did not
change expression of VEGFR2, VE-cadherin CD144 or an-
giogenic marker CD31. Based on the data we excluded that
increased tumor initiation could be due to a vasculogenic
mimicry [40].
SU11274 was previously shown to alter expression
profile of the treated cells attributed to its off-target ac-
tion. Thirty-nine genes belonging to the apoptosis/necro-
sis, inflammation, oxidative/metabolic stress, heat shock,
proliferation/carcinogenesis and growth arrest/senescence
pathways were altered at least 2-fold (by increasing or de-
creasing them) by SU11274 in ovarian cancer cells [41].
These data show its broader action and capability to in-
duce multiple target genes involved in oxidative and meta-
bolic stress [41], so this compound cannot be considered
as a c-Met specific inhibitory agent. Crizotinib represents
more targeted agent in comparison to SU11274 and it did
not alter cellular ATP content in treated cells. Based on
Table 1 Frequency of tumor initiating cells
Confidence intervals for 1/(stem cell frequency)
Rel3 Lower Estimate Upper
Spheroid cells 84,848 33,233 13,016
SU11274-treated spheroid cells 7208 3289 1501
M14 Lower Estimate Upper
Spheroid cells 168,352 38,964 9018
SU11274-treated spheroid cells 29,964 10,211 3479
Human melanoma cells were cultured in non-adherent conditions for 7 days
in the presence or absence of 1 μM SU11274. Cells were counted, diluted in
1:1 serum-free medium: ECM gel and injected s.c. (n= 4/each group). Following
numbers were injected: 50,000; 10,000; 5000; 1000; 500; 100; 50 and 10 Rel3 cells,
and 20,000; 2000; 200 and 20 M14 cells based on preliminary test of tumorigenicity.
Stem cell frequency was calculated by ELDA analysis, p value was≤ 10−5 for the
Rel3 cells, and ≤ 0.05 for the M14 cells. The tumor take rate was significantly higher
in the SU11274-treated cells: 3 out of 4 inoculations of 500 SU11274-treated EGFP-
A375/Rel3 cells gave tumors in contrast to 0 out of 4 inoculations of the untreated
cells. Similarly, 4 out of 4 inoculations of 2000 SU11274-treated M14 cells gave
tumors in contrast to 0 out of 4 inoculations of the untreated M14 cells
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Fig. 4 SU112747 mediated bioenergetic alterations. a Melanoma cells Rel3 were serially passaged in spheroid culture conditions. Cumulative cell numbers
were counted from the number of expanded cells and the inoculum used for each passage. There was a significant difference between the number of
cells in SU11274-treated versus untreated cultures with a substantial inhibition of the cell proliferation with 1 μM SU11274. Melanoma cells could be serially
propagated the presence of inhibitor (≥10 passages), thus demonstrating that SU11274 does not compromise long-term proliferation potential in vitro.
b Rel3 cells from the spheroid cultures were trypsinized and plated in adherent culture conditions. Long-term propagation with or without SU11274 shifted
cellular morphology from irregular spiked shape to flatter cobblestone morphology and less scattered colonies. c Two independent methods
were compared to evaluate effect of the treatment with 1 μM SU11274 for 6 days on cell proliferation. Luminescent ATP-based assay has
shown 9.4 % inhibition only in contrast to the 39.5 % inhibition of proliferation as determined by relative BrdU incorporation assay. d M14,
EGFP-A375 and Rel3 cells were treated with 1 μM SU11274 in spheroid conditions for 7 days. Spheroids were trypsinized, viable cell counts determined, cell
suspension was mixed with the luminescent reagent from the Luminescent ATP-based Assay and relative ATP-production per 100,000 cells was calculated
at least in quadruplicates. SU11274 treatment significantly increased the relative ATP-content per cell in comparison to untreated controls. e–f Same
treatments as in Fig. 4d. were used to determine glucose uptake and lactate release by colorimetric method. Values were expressed as mean + SD, there
was no significant difference in glucose uptake between the SU11274-treated and untreated cells. SU11274-treated cells exhibited significantly higher levels
of released lactate in comparison to untreated cells, *p< 0.05
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the correlation to SU11274-mediated increase in tumor
initiation in vivo we concluded that the off-target action
of SU11274 is responsible for its protumorigenic action.
Furthermore, it favors our hypothesis that melanoma-
initiating capability is linked to the metabolic state of cells.
The experiments investigating these effects in other tumor
types might bring further insight how altering bioener-
getic state might potentially support the tumor initi-
ation. SU11274 upregulated almost 2-fold several stem
cell markers (Oct3/4, Nanog, AFP and Gata4) in treated
cells (Fig. 5a). It also increased activity of RSK1/2/3 kinase
based on the phosphotyrosine array analysis. Martin et al.
[25] also reported increased ERK activity resulting in RSK1
activation correlating with protumorigenic action in met-
formin treated melanoma cells A375. However, our data
did not confirm any VEGF expression upon SU11274 treat-
ment in contrast to their conclusions that VEGFA upregu-
lation led to protumorigenic action of metformin [25]. It
suggested that SU11274 compound exerts its protumori-
genic action in the absence of increased VEGF secretion
and prompted us to examine bioenergetic regulation.
As recently reviewed, increasing evidence suggests that
many types of stem cells rely on anaerobic glycolysis and
their stem cell function is regulated by bioenergetic sig-
naling [22, 42]. Similar mechanisms might be operating
in cancer stem cells, in fact some studies have already
Fig. 5 Bioenergetic modulation counteracts the protumorigenic action of the SU11274. a–b Protein lysates were prepared from untreated controls
and Rel3 cells treated with 1 μM SU11274 in spheroid conditions for 7 days. Pluripotent stem cell array has shown expression of all pluripotency
markers in Rel3 cells expanded as spheroids. SU11274 treatment further increased level of proteins associated with pluripotency in SU11274-treated
cells correlating with their higher tumor initiating properties. Phosphokinase assay screening has shown several active intracellular signaling cascades.
Phosphorylated forms of p53 (S392 and S46) were detected in the SU11274-treated cells (lower panel B), which correlates with SU11274 mediated
inhibition of cell proliferation. RSK1/2/3 (S380) phosphorylation was increased in SU11274-treated cells. We detected phosphorylation of the following
target kinases: ERK1/2 (T202/Y204, T185/Y187), P-RAS40 (T246), Akt 1/2/3 (S473), p38 alpha (T180/Y182), AMPK alpha1 (T183), CREB (S133), GSK-3 alpha/
beta(S21/S9), WNK-1 (T60) and HSP60 in both treated and untreated cells
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suggested critical role of the metabolic de-regulation for
stemness [43]. These findings open novel therapeutic
intervention points in cancer. Liu et al. suggested that
glycolytic inhibitor 3-BrOP could be combined with
standard chemotherapy to target both side population
and bulk tumor mass. It was sufficient to treat cells for
24 h with 3-BrOP to achieve antitumor effect in contrast
to a platinum-derived agent, which did not affect tumor
growth whilst sparing the side population [38]. Higher
glycolytic rate seems to be a general characteristic of
melanoma cells. Oncogene BRAF, which is constitutively
activated also in our melanoma model Rel3 was impli-
cated to be directly involved in reprogramming of cellular
metabolism. Dichloroacetate (DCA) as a pyruvate de-
hydrogenase kinase inhibitor, exerted antimelanoma effect
and potentiated its response to specific BRAF inhibition
by vemurafenib [21]. Chemosensitivity was not signifi-
cantly altered in the SU11274-treated cells in vitro and in
vivo. We were not able to find any combination of the
SU11274 molecule with another chemotherapeutic drug
to achieve synthetic lethality (data not shown).
Over the last years, several strategies to target melanoma
stem cells were suggested [44, 45]. There were attempts to
target a self-renewal pathway of melanoma stem cells thus
disabling their ability to replicate as rewieved in [11].
Bioenergetic modulation seems to emerge as novel
Fig. 6 SU11274-mediated increase of tumor initiation can be reverted by bioenergetics odulation ith dichloroacetate. a–c Sensitivity to glycolytic
modulators 3-BrPA, DCA and dacarbazine in adherent and spheroid cultures was compared. Spheroid Rel3 are significantly more sensitive to 3BrPA
and DCA, significantly more resistant to dacarbazine. Relative viability was determined by luminescent ATP-based assay. Values were calculated from
quadruplicates as means + SD, *p < 0.05. d–e Rel3 cells were treated with SU11274 in spheroid conditions for 7 days. Following drugs were added for
24 h on day 4 after treatment start: 5 mM DCA, 3.5 μM 3BrPA or 100 μM dacarbazine (DACA). Cells were let to recover for next 48 h in the presence of
inhibitor SU11274 only. Spheroids were trypsinized, viable cell counts determined, ATP per cell determined by bioluminescent assay. Then, 1 × 104 cells
were mixed with the ECM Gel diluted in serum-free medium and injected s.c. DCA did not change SU11274-mediated increase of the ATP-level per
cell, 3BrPA and dacarbazine further increased the ATP level. DCA treatment alone in Rel3 cells did not significantly affect tumor growth or initiation.
DCA treatment delayed the tumor onset in SU11274 treated cells and significantly inhibited tumor growth as determined by day 21, *p < 0.05
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strategy to target melanoma cancer stem cells. In our
work, we present data from the experiments in vivo,
which support this hypothesis. Protumorigenic action
of small molecule SU11274 could be counteracted by
bioenergetic modulator dichloroacetate. On the other
hand, glycolytic inhibitor 3-bromopyruvate did not
prove suitable, thus showing the specificity in the sig-
naling cascade induced by SU11274 in melanoma cells.
More importantly, we observed no antitumorigenic ac-
tion when dacarbazine was used. Our study further
underlines the importance of drug testing in non-
adherent spheroid cultures as these might better reflect
the efficiency against tumor initiating cells [46].
Conclusions
Our work highlights a role of bioenergetic modulation
in melanoma initiation. It shows that antiproliferative ef-
fect in vitro can actually lead to increased tumorigenicity
in vivo. In summary, melanosphere cultures were sub-
stantially enriched for melanoma-initiating cells in vivo
in the absence of any alteration in cancer stem cell
markers. Small molecule SU11274 originally intended as
a specific c-Met inhibitor significantly reduces melano-
sphere proliferation, but increases intracellular ATP con-
tent, which correlates with an increased tumorigenicity.
Tumorigenicity could be reduced in SU11274-treated
cells by bioenergetic modulator DCA indicating that
glycolytic inhibition could counteract SU11274 mediated
effect on melanoma initiation.
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